Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure
Top Cited Papers
- 25 September 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 116 (13) , 1482-1487
- https://doi.org/10.1161/circulationaha.107.696906
Abstract
Background— Patients with chronic heart failure (HF) are at increased risk of both fatal and nonfatal major adverse cardiovascular events. We used data from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) trials to assess the influence of nonfatal hospitalizations for HF on subsequent mortality rates in a broad spectrum of HF patients. Methods and Results— In the present study, 7599 patients with New York Heart Association class II to IV HF and reduced or preserved left ventricular ejection fraction were randomized to placebo or candesartan. We assessed the risk of death after discharge from a first hospitalization for HF using time-updated Cox proportional-hazards models on 7572 patients for whom discharge data were available. Of 7572 patients, 1455 (19%) had at least 1 HF hospitalization, and 586 of 1819 deaths occurred after discharge from an HF hospitalization. The mortality rate was increased after HF hospitalizations, even after adjustment for baseline predictors of death (hazard ratio, 3.15; 95% confidence interval, 2.83 to 3.50). Longer duration of HF hospitalization enhanced the risk of dying, as did repeat HF hospitalizations. Moreover, risk of death was highest within a month of discharge and then declined progressively over time, particularly for death resulting from HF progression and for sudden cardiac death. We observed a similar pattern of risk associated with all-cause hospitalization, although the magnitude was less than that with HF hospitalization. Conclusions— In patients with chronic HF, the risk of death is greatest in the early period after discharge after a hospitalization for HF and is directly related to the duration and frequency of HF hospitalizations. These findings suggest a role for increased surveillance in the early postdischarge period of greatest vulnerability after an HF admission.Keywords
This publication has 16 references indexed in Scilit:
- Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure TrialsCirculation, 2006
- Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure PatientsCirculation, 2005
- Predictors of mortality and morbidity in patients with chronic heart failureEuropean Heart Journal, 2005
- Heart failureThe Lancet, 2005
- Effect of Candesartan on Cause-Specific Mortality in Heart Failure PatientsCirculation, 2004
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialThe Lancet, 2003
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialThe Lancet, 2003
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeThe Lancet, 2003
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999